Ugint Co Ltd (195990) - Total Liabilities

Latest as of March 2026: ₩22.30 Billion KRW ≈ $15.11 Million USD

Based on the latest financial reports, Ugint Co Ltd (195990) has total liabilities worth ₩22.30 Billion KRW (≈ $15.11 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 195990 long-term investment intensity to see how much of total assets are deployed in long-term investments.

Ugint Co Ltd - Total Liabilities Trend (2014–2025)

This chart illustrates how Ugint Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 195990 asset base.

Ugint Co Ltd Competitors by Total Liabilities

The table below lists competitors of Ugint Co Ltd ranked by their total liabilities.

Company Country Total Liabilities
Nosa Med AB
ST:NOSA
Sweden Skr23.65 Million
SILVER DOLLAR RES
F:4YW
Germany €31.27K
Impedimed Ltd
AU:IPD
Australia AU$29.34 Million
Bytes Technology Ltd
LSE:BYIT
UK GBX393.01 Million
Pluri Inc.
NASDAQ:PLUR
USA $39.06 Million
Thunderful Group AB
ST:THUNDR
Sweden Skr172.90 Million
Glen Burnie Bancorp
NASDAQ:GLBZ
USA $373.70 Million
Mcphersons Ltd
AU:MCP
Australia AU$45.97 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Ugint Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 195990 equity financing ratio to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.16 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.39 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.28 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ugint Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ugint Co Ltd (2014–2025)

The table below shows the annual total liabilities of Ugint Co Ltd from 2014 to 2025.

Year Total Liabilities Change
2025-12-31 ₩20.75 Billion
≈ $14.06 Million
-37.60%
2024-12-31 ₩33.25 Billion
≈ $22.53 Million
+68.19%
2023-12-31 ₩19.77 Billion
≈ $13.40 Million
+20.18%
2022-12-31 ₩16.45 Billion
≈ $11.15 Million
-45.79%
2021-12-31 ₩30.34 Billion
≈ $20.56 Million
+12.68%
2020-12-31 ₩26.93 Billion
≈ $18.25 Million
-61.91%
2019-12-31 ₩70.70 Billion
≈ $47.91 Million
+1.59%
2018-12-31 ₩69.59 Billion
≈ $47.16 Million
-6.33%
2017-12-31 ₩74.29 Billion
≈ $50.35 Million
+30.88%
2016-12-31 ₩56.77 Billion
≈ $38.47 Million
+71.06%
2015-12-31 ₩33.18 Billion
≈ $22.49 Million
-36.93%
2014-12-31 ₩52.62 Billion
≈ $35.66 Million
--

About Ugint Co Ltd

KQ:195990 Korea Specialty Industrial Machinery
Market Cap
$12.95 Million
₩19.12 Billion KRW
Market Cap Rank
#26481 Global
#2001 in Korea
Share Price
₩1174.00
Change (1 day)
+0.00%
52-Week Range
₩140.00 - ₩2415.00
All Time High
₩3950.00
About

RootK Co., Ltd. manufactures and sells machine tools and biotechnology products in South Korea and internationally. It offers tapping centers, spindle machines, machining and turning centers, and machining centers with long table. Additionally, It also offers bispecific antibody therapeutics for ophthalmic and oncology indications, including anti-VEGF/ANG2, anti-HER2/CD3, anti-GPC3/CD3, and anti-… Read more